Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study)
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 7950-7963
DOI: 10.1111/dom.70946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 16.06.2026. Verfasst von William Hinton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort study with a prevalent new‐user design using pseudonymised data from the Oxford‐Royal College of General Practitioners Research and Surveillance Centre primary care sentinel network. We extracted data for two cohorts prescribed SGLT2is and/or GLP‐1 RAs between January 2013 and December 2021. We 1:1 propensity score matched SGLT2i plus GLP‐1 RA combination users with monotherapy (SGLT2i or GLP‐1RA) users. Multivariable linear regression analyses estimated adjusted mean differences in absolute change in estimated glomerular filtration rate (eGFR) (baseline to 1‐ and 2‐years follow‐up) between combination and monotherapy.
Results
Across the matched combination and SGLT2i monotherapy groups ( N = 14 774), mean decline in eGFR, baseline to 1‐year, was −4.5 mL/min/1.73 m 2 and 2‐years, −5.0 mL/min/1.73 m 2 , with no difference when comparing combination and SGLT2i monotherapy. Across the matched combination and GLP‐1 RA monotherapy groups ( N = 14 154), mean decline in eGFR, baseline to 1‐year, was −5.4 mL/min/1.73 m 2 and 2‐years, −6.1 mL/min/1.73 m 2 , but combination therapy was associated with a smaller eGFR reduction compared with GLP‐1 RA monotherapy (difference in eGFR at 1‐year: [mean, 95% confidence interval, CI] 2.2, 1.7 to 2.8, p < 0.001; and at 2‐years: 2.1, 1.4–2.7, p < 0.001).
Conclusions
In real‐world clinical practice, the combination of SGLT2i and GLP‐1 RA may be more effective for preserving kidney function than GLP‐1 RA monotherapy. This effect was not seen with combination versus SGLT2i monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
- Renal Services, Epsom and St. Helier University Hospitals NHS Trust, London, UK.
- Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, UK.
- Centre for Kidney and Bladder Health, University College London, London, UK.
ORCID-Profile: William Hinton, Martin B Whyte, Bernardo Meza-Torres, Simon de Lusignan
Förderung
- Merck Sharp & Dohme Ltd.
Zitieren
APA
Hinton, W., Joy, M., Forbes, A. K., Whyte, M. B., Ordóñez-Mena, J. M., Fan, X., Ferreira, F., Meza-Torres, B., Munro, N., de Lusignan, S., Wheeler, D. C., & Feher, M. D. (2026). Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study). Diabetes, Obesity and Metabolism, 28(9), 7950-7963. https://doi.org/10.1111/dom.70946
Vancouver
Hinton W, Joy M, Forbes AK, Whyte MB, Ordóñez-Mena JM, Fan X, et al. Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study). Diabetes, Obesity and Metabolism. 2026;28(9):7950-7963. doi:10.1111/dom.70946
BibTeX
@article{Hinton2026,
author = {Hinton, William and Joy, Mark and Forbes, Anna K and Whyte, Martin B and Ordóñez-Mena, José M and Fan, Xuejuan and Ferreira, Filipa and Meza-Torres, Bernardo and Munro, Neil and de Lusignan, Simon and Wheeler, David C and Feher, Michael D},
title = {Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study)},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {7950--7963},
doi = {10.1111/dom.70946}
}
EUVIMED